J.P. Morgan analyst Julia Qin maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) on November 4 and set a price target of $18.00. The company’s shares closed last Friday at $8.89.
According to TipRanks, Qin is a 3-star analyst with an average return of 2.1% and a 54.05% success rate. Qin covers the Healthcare sector, focusing on stocks such as Invitae, Seer, and Singular Genomics Systems.
Adaptive Biotechnologies has an analyst consensus of Hold, with a price target consensus of $11.13, implying a 25.20% upside from current levels. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $13.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $37.55 and a one-year low of $5.96. Currently, Adaptive Biotechnologies has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
Read More on ADPT:
- Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
- Natera named top pick in minimal residual disease at Piper Sandler
- Adaptive price target lowered to $7.50 from $12 at Piper Sandler
- Adaptive Biotechnologies partners with Epic to increase access to MRD monitoring
- Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
